Blood
Articles in this Issue
Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial
Abstract Background: Patients newly diagnosed with multiple myeloma (NDMM) harboring high-risk (HR) factors typically have a poor prognosis....
MC210807: Phase 1 clinical trial assessing the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in Relapsed/Refractory myeloproliferative chronic myelomonocytic leukemia (CMML).
Abstract BACKGROUND: DNA methyltransferase inhibition offers palliative benefit but does not alter disease biology. in chronic myelomonocyti...
Assessment of red blood cell functional biomarkers following hematopoietic cell transplantation in sickle cell disease patients
Abstract Introduction:Sickle cell disease (SCD) is caused by a mutation in the β-globin gene (HBB) that causes red blood cells (RBC) to sick...
Real-world barriers to treatment access in T-cell lymphoma
Abstract Introduction T-cell lymphomas (TCL) are associated with limited therapeutic options and poor outcomes. Identifying real-world barri...
Stepwise leukemogenesis and therapeutic targets revealed in B-cell acute lymphoblastic leukemia driven by PAX5 mutations
Abstract PAX5 is genetically altered in over 30% of B-ALL cases, with point mutations representing the second most common type of alteration...
Real life treatments and outcomes of older patients aged more than 60 years with FLT3-mutated acute myeloid leukemia: Report from the multicentric french observational ALFA-PPP study
Abstract Introduction. Based on the results of the phase 3 RATIFY trial (Stone et al, NEJM, 2017), 7+3 (daunorubicin/cytarabine) plus midost...
Feasibility of anti-BCMA CAR-T therapy in a middle-income country
Abstract Background: Ciltacabtagene autoleucel (cilta-cel) was approved in Brazil in April 2024 and is currently the only BCMA-directed CAR-T...
Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis
Abstract Introduction: Anemia is a common and clinically significant manifestation of myelofibrosis (MF). Both anemia and transfusion depend...
Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma
Abstract Background: Clonal hematopoiesis of indeterminate potential (CHIP) has been linked to impaired hematopoietic recovery and adverse o...
Epidemiology, risk factors, and outcomes of cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplantation: A retrospective observational single-centre study from western India
Abstract Background: Cytomegalovirus (CMV) reactivation is a major post-transplant complication, especially in allogeneic hematopoietic stem...
Results of part 1 of a two-part study evaluating the combination of tazemetostat and CPX-351 (part 1) and palbociclib with CPX-351 (part 2) for the treatment of relapsed or refractory Acute Myeloid Leukemia
Abstract INTRODUCTION For fit patients (pts) with acute myeloid leukemia (AML), conventional chemotherapy (chemotx) with...
Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study
Abstract Introduction: The safety and efficacy established by daratumumab (a CD38 monoclonal antibody)-based induction therapies for both tr...
Real world outcomes of asciminib in relapsed/refractory Philadelphia chromosome positive B-ALL and blast Phase CML
Abstract Background Asciminib is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor with distinct activity ag...
MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”
Abstract Myeloproliferative neoplasms (MPN) harboring concurrent mutations in more than one driver gene represent an increasingly recognized...
Treatment inequities in newly diagnosed diffuse large B-cell lymphoma (DLBCL): Comparing polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) vs rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) among Medicare beneficiaries
Abstract Background: The 5-year follow-up of the Phase III POLARIX trial confirmed a sustained progression-free survival benefit of Pola-R-C...
Association of anxiety and depression with cannabis usage disorder among thalassemia patients: A national inpatient sample analysis
Abstract Introduction: With increasing cannabis usage in the United States, a mounting association with mental health disorders is observed....
Prevalence of iron deficiency with or without anemia in adults: A systematic review and meta-analysis
Abstract Background/Purpose: Iron deficiency (ID) with or without anemia is a prevalent health problem. Iron deficiency anemia (IDA) affects...
Incidence of infectious complications in Acute Myeloid Leukemia patients undergoing induction chemotherapy with or without fluoroquinolone prophylaxis in real-life: Results from INFLUENCER study
Abstract INTRODUCTION In Acute Myeloid Leukemia (AML) patients, Febrile Neutropenia (FN) is the main cause of non-relapse mortality, especial...
Expansion, differentiation, and culture of hematopoietic stem & progenitor cells using an ancillary GMP-compliant medium
Abstract Hematopoietic stem and/or progenitor cells (HSPCs) from human primary or pluripotent stem cells (hPSCs) and their derivatives, natu...
Distinct patterns of bone marrow complement and immunoglobulin deposition define unique clinicopathologic phenotypes in myelodysplastic neoplasms
Abstract Background: Immune dysregulation and complement activation are implicated in bone marrow failures, but their specific roles in myel...
Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India
Abstract INTRODUCTION The intensive 3+7 regimen is the standard induction therapy for acute myeloid leukemia (AML). However, a significant p...
Outcomes of standard versus reduced-doses post-transplant cyclophosphamide prophylaxis in matched sibling donor allogeneic hematopoietic cell transplant: A retrospective study at a single tertiary center in Saudi Arabia
Abstract Introduction: Post-transplant cyclophosphamide (PTCy) Initially emerged in haploidentical allogeneic hematopoie...
Strategies for improving clinical documentation in cancer care and implications for reproductive health: A scoping review
Abstract Background: High quality clinical documentation is central to ensuring optimal patient care, reducing medical errors, and empowerin...
Impact of induction regimen and co-mutations on outcomes in AML with myelodysplasia-related changes
Abstract Introduction: Limited studies have evaluated the efficacy of different induction regimens in patients with acute myeloid leukemia w...
Administration of chemoterapy at home for “unfit” hematological patients: A safe and cost-effective way.
Abstract Thanks to scientific research in hematology, there has been a progressive improvement in therapeutic prospects. However, this scien...